Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019046600) INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-1R) BINDING PROTEINS AND METHODS OF USE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/046600 International Application No.: PCT/US2018/048889
Publication Date: 07.03.2019 International Filing Date: 30.08.2018
IPC:
A61P 9/00 (2006.01) ,A61P 43/00 (2006.01) ,C07K 16/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
COHEN, Pinchas [US/US]; US
AMGEN INC. [US/US]; One Amgen Center Drive Thousand Oaks, CA 91320-1799, US
ALBERT EINSTEIN COLLEGE OF MEDICINE [US/US]; 1300 Morris Park Avenue Bronx, NY 10461, US
Inventors:
COHEN, Pinchas; US
BELTRAN, Pedro; US
HUFFMAN, Derek; US
BARZILAI, Nir, M.D.; US
Agent:
HONG, Julie J.; US
HONG, Julie, J.; US
Priority Data:
62/552,36030.08.2017US
62/575,93723.10.2017US
Title (EN) INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-1R) BINDING PROTEINS AND METHODS OF USE
(FR) PROTÉINES DE LIAISON DU RÉCEPTEUR DU FACTEUR DE CROISSANCE 1 APPARENTÉ À L'INSULINE (IGF-1R) ET PROCÉDÉS D'UTILISATION
Abstract:
(EN) The present disclosure provides a method of improvement, preservation, prophylaxis, or inhibition-of-deterioration of a healthspan parameter of a mammalian subject. In exemplary embodiments, the method comprises administering to the subject a composition that comprises an insulin-like growth factor-1 receptor (IGF-1 R) inhibitor, wherein the composition is administered in an amount effective to improve, provide prophylaxis for, or inhibit-the-deterioration of the healthspan parameter.
(FR) La présente invention concerne un procédé d'amélioration, de conservation, de prophylaxie ou d'inhibition de la détérioration d'un paramètre de durée de vie en santé d'un sujet mammifère. Dans des modes de réalisation donnés à titre d'exemple, le procédé comprend l'administration au sujet d'une composition qui comprend un récepteur du facteur de croissance 1 apparenté à l’insuline (IGF-1R), la composition étant administrée en une quantité efficace pour améliorer, fournir une prophylaxie pour, ou inhiber la détérioration du paramètre de durée de vie en santé.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)